Recent

% | $
Quotes you view appear here for quick access.

OncoSec Medical Incorporated Message Board

  • brotherbear44 brotherbear44 Apr 4, 2014 5:44 PM Flag

    With the Amgen news today I thought I would post this again

     

    I have posted this a few times and thought I would again considering the Amgen news. Just a quick comparison to show how ONCS continues to be severely undervalued and has the potential for substantial growth from its current pps. These are 3 acquisitions from the past few years.

    Amgen-BioVex $1B
    $425MM in cash plus $575MM in payments for regulatory and sale milestones
    1 drug in Phase 3 that was recruiting patients
    1 drug under development in the UK
    An operational manufacturing facility

    Amgen-Micromet $1.16B in cash
    1 drug under going multiple trials with no further progression than ongoing Phase 2s
    Proprietary BiTE antibody technology for future research and potential milestone/royalty payments from licensing
    Rights to one antibody in Phase 1
    A site for R&D

    Celgene-Avila $925MM
    $350MM in cash plus $195MM for milestones of the drug's successful development and approval, plus $380MM for milestones from drugs developed and approved from the platform
    1 drug in Phase 1
    Proprietary Avilomics Platform for discovery and development

    What does OncoSec have to offer:
    NeoPulse:
    Ready for market in Europe
    CE Mark for Europe,
    Patent for China for method of use and device.
    ImmunoPulse:
    Patent Protection through 2024
    Phase 2 Malignant Melanoma, planned Phase 2B combo w/ anti-PD-1(potential BD and AA)
    Phase 2 Merkel Cell Carcinoma (potential OD/OA)
    Phase 2 Cutaneous T-cell Lymphoma
    Producing outstanding data thus far, in fact leading the way with their results
    The SRA with Old Dominion
    Soon to be new clinical trial for ImmunoPulse w/anti-PD-1
    Expected Partnership announcement.
    Cash on hand to run through 2015
    Along with some other "assets" OncoSec acquired from INO that have yet to be disclosed publicly.

    ONCS is severely undervalued with its current MC of $175MM and if things line up as they have the potential to, then ONCS shareholders will be rewarded several times over.

    Sentiment: Strong Buy

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
ONCS
0.35+0.01(+3.40%)Mar 27 3:57 PMEDT